Director Laurence Charney has sold 22,000 shares of TG Therapeutics Inc (TGTX, Financial) on March 12, 2024, according to a recent SEC Filing. Over the past year, the insider has sold a total of 39,500 shares of the company and has not made any purchases.
TG Therapeutics Inc is a biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company aims to improve the quality of life and health of patients with chronic lymphocytic leukemia, non-Hodgkin's lymphoma, and multiple sclerosis.
The insider transaction history for TG Therapeutics Inc indicates a pattern of insider selling, with 5 insider sells and only 1 insider buy over the past year.
Shares of TG Therapeutics Inc were trading at $15.97 on the day of the insider's recent transaction, giving the company a market cap of $2.429 billion. The price-earnings ratio stands at 1,573.00, which is significantly higher than the industry median of 29.16 and also above the company's historical median price-earnings ratio.
The stock's price-to-GF-Value ratio is 0.05, with a GF Value of $324.76, indicating that TG Therapeutics Inc is considered a Possible Value Trap, Think Twice based on its GF Value. The GF Value is calculated using historical trading multiples, a GuruFocus adjustment factor based on past returns and growth, and future business performance estimates from Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
